Mission
Mission
Mission
At Interface Bio, we are building a drug company at the frontier of innovation through the development of multi-targeted immunotherapies.
At Interface Bio, we are building a drug company at the frontier of innovation through the development of multi-targeted immunotherapies.
Complex diseases like autoimmune disorders and cancer require multi-mechanism therapies (e.g. ADCs, bi-specifics), but developing these drugs is challenging due to interaction effects, toxicity, and high costs. Interface Biosciences takes a different approach. Natural products produced and optimized by commensals in the human body are the world's best source of safe and effective therapeutics. Our platform leverages these chemical scaffolds using our AI-guided search strategies and optimization to generate next-generation immunotherapy assets at an unprecedented rate.
Complex diseases like autoimmune disorders and cancer require multi-mechanism therapies (e.g. ADCs, bi-specifics), but developing these drugs is challenging due to interaction effects, toxicity, and high costs. Interface Biosciences takes a different approach. Natural products produced and optimized by commensals in the human body are the world's best source of safe and effective therapeutics. Our platform leverages these chemical scaffolds using our AI-guided search strategies and optimization to generate next-generation immunotherapy assets at an unprecedented rate.
Mission
At Interface Bio, we are building a drug company at the frontier of innovation through the development of multi-targeted immunotherapies.
Complex diseases like autoimmune disorders and cancer require multi-mechanism therapies (e.g. ADCs, bi-specifics), but developing these drugs is challenging due to interaction effects, toxicity, and high costs. Interface Biosciences takes a different approach. Natural products produced and optimized by commensals in the human body are the world's best source of safe and effective therapeutics. Our platform leverages these chemical scaffolds using our AI-guided search strategies and optimization to generate next-generation immunotherapy assets at an unprecedented rate.
Technology
Technology
Technology
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Commensal microbes have coevolved with humans for millions of years, giving rise to a massive repertoire of non-toxic, bioactive, and multi-mechanism molecules. By combining precision culturomics, targeted metabolomics, molecular engineering, and AI, Interface Bio’s platform mines these natural product libraries to develop next generation, multi-mechanism therapeutics.
Commensal microbes have coevolved with humans for millions of years, giving rise to a massive repertoire of non-toxic, bioactive, and multi-mechanism molecules. By combining precision culturomics, targeted metabolomics, molecular engineering, and AI, Interface Bio’s platform mines these natural product libraries to develop next generation, multi-mechanism therapeutics.
Commensal microbes have coevolved with humans for millions of years, giving rise to a massive repertoire of non-toxic, bioactive, and multi-mechanism molecules. By combining precision culturomics, targeted metabolomics, molecular engineering, and AI, Interface Bio’s platform mines these natural product libraries to develop next generation, multi-mechanism therapeutics.
Commensal microbes have coevolved with humans for millions of years, giving rise to a massive repertoire of non-toxic, bioactive, and multi-mechanism molecules. By combining precision culturomics, targeted metabolomics, molecular engineering, and AI, Interface Bio’s platform mines these natural product libraries to develop next generation, multi-mechanism therapeutics.
Technology
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Commensal microbes have coevolved with humans for millions of years, giving rise to a massive repertoire of non-toxic, bioactive, and multi-mechanism molecules. By combining precision culturomics, targeted metabolomics, molecular engineering, and AI, Interface Bio’s platform mines these natural product libraries to develop next generation, multi-mechanism therapeutics.
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
02
Screen
After production of our high-value sactipeptide libraries, we use targeted screens to identify assets with high potency against previously intractable targets.
02
Screen
After production of our high-value sactipeptide libraries, we use targeted screens to identify assets with high potency against previously intractable targets.
02
Screen
After production of our high-value sactipeptide libraries, we use targeted screens to identify assets with high potency against previously intractable targets.
03
Optimize
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
03
Optimize
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
03
Optimize
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
04
Validate
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
04
Validate
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
04
Validate
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
01
Build
We build libraries of microbial derived natural products that have a high potential for bioactivity. Our chemical libraries are curated from 1) Previously isolated microbial products that have not been tested for their potential as therapeutics and 2) Microbes grown up in culture with uncharacterized metabolites.
02
Screen
03
Optimize
04
Validate
01
Build
We build libraries of microbial derived natural products that have a high potential for bioactivity. Our chemical libraries are curated from 1) Previously isolated microbial products that have not been tested for their potential as therapeutics and 2) Microbes grown up in culture with uncharacterized metabolites.
02
Screen
03
Optimize
04
Validate
01
Build
We build libraries of microbial derived natural products that have a high potential for bioactivity. Our chemical libraries are curated from 1) Previously isolated microbial products that have not been tested for their potential as therapeutics and 2) Microbes grown up in culture with uncharacterized metabolites.
02
Screen
03
Optimize
04
Validate
Get in Touch
Get in Touch
Reach out if you are interested in working with us or would like to learn more about how natural products could revolutionise the chemical space
Reach out if you are interested in working with us or would like to learn more about how natural products could revolutionise the chemical space
Get in Touch
Reach out if you are interested in working with us or would like to learn more about how natural products could revolutionise the chemical space
